Abstract 16713: Lipoprotein(a) and Risk of Incident Cardiovascular Events in Patients with Established Atherosclerotic Disease
Abstract
Introduction: Lipoprotein(a) [Lp(a)] is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease. Its prognostic significance in patients with already-established atherosclerosis remains unclear. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network (2006-2026). Adults aged 18 years or older with a diagnosis of atherosclerosis and a measured Lp(a) were classified as elevated (≥125 nmol/L or ≥50 mg/dL) or non-elevated (<125 nmol/L or <50 mg/dL). The index date was the date of atherosclerosis diagnosis. Cohorts were 1:1 propensity-score matched on demographics (age, sex, race, BMI) comorbidities (diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, tobacco use, chronic ischemic heart disease), medication (statins, PCSK9-I, ACE-I, ARB, anticoagulants) and stratified LDL cholesterol. Primary outcomes were carotid artery stenosis and myocardial infarction (MI). Secondary outcomes included peripheral artery disease (PAD), MACE and mortality. Outcomes were assessed from 30 days to 5 years after index. Hazard ratios (HR) were estimated by Cox proportional-hazards analysis. Results: After matching, 11,217 patients per group were well-balanced across all covariates (SMD<0.1), including age (65.2 vs 65.0), sex (51.0% male vs 51.3% male) and 6 different LDL buckets. Over 5 years, elevated Lp(a) was associated with higher risk of carotid artery stenosis (HR 1.28, 95% CI 1.17-1.40, p<0.01), PAD (HR 1.26, 95% CI 1.14-1.38, p<0.01), MI (HR 1.15, 95% CI 1.03-1.27, p=0.01), and MACE (HR 1.13, 95% CI 1.04-1.24, p<0.01). No association was seen for stroke (HR 1.05, 95% CI 0.94-1.16, p=0.39) or all-cause mortality (HR 0.94, 95% CI 0.84-1.06, p=0.30). Conclusions: In a large, propensity-matched multinational cohort of patients with established atherosclerosis, elevated Lp(a) was independently associated with incident myocardial infarction, carotid artery stenosis, peripheral artery disease, and MACE, but not with stroke or mortality at 5 years. These findings suggest that elevated Lp(a) contributes to atherosclerotic progression across multiple vascular territories.